PRINCETON, NJ--Bristol-Myers Squibb announced it will license the use of Acacia Biosciences' proprietary Genome Reporter Matrix, a technology to identify changes in the expression of thousands of genes in the presence of potential therapeutic compounds. Bristol-Myers Squibb will use the matrix to develop pharmaceutical compound profiles that can help researchers understand the therapeutic benefits and potential side effects of compounds, as well as identify novel targets for drug discovery.
The agreement includes an up-front payment for technology evaluation. Acacia will profile a limited number of potential therapeutic compounds for a fixed fee. Elliott Signal, vice-president of applied genomics for Bristol-Myers Squibb, said Acacia's profiling technology adds to his company's ability to enhance existing therapies and develop novel medicines.